Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-virus-specific T cells TI1
- Development stage
- Unknown
- Lead developer
- QIMR Berghofer Medical Research Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Multi-virus-specific T cells TI1 is an investigational allogeneic cellular immunotherapy developed by the QIMR Berghofer Medical Research Institute. The therapy consists of donor-derived (allogeneic) T cells specifically trained to target antigens from four common opportunistic viruses: cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK polyomavirus (BKV), and adenovirus (AdV). It is designed to restore virus-specific cellular immunity in immunocompromised patients, particularly adult solid organ transplant (SOT) recipients and pediatric hematopoietic stem cell transplant (HSCT) recipients who suffer from refractory or contraindicated viral infections. Administered via intravenous infusion, the therapy aims to provide a safe and effective alternative to conventional antiviral drugs, which are often limited by toxicity and the emergence of drug-resistant strains.
- Other names
- multi-virus-specific T cells TI1multi-virus-specific T-cell therapy TI1
02
Targets
Epstein-Barr virus viral antigens presented as peptide-human leukocyte antigen complexespMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)Adenovirus viral antigens presented as peptide-HLA complexes
Beyond the preview
Go deeper on multi-virus-specific T cells TI1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-virus-specific T cells TI1.